MICROSURE
7.6.2019 12:39:10 CEST | Business Wire | Press release
MUSA is the world’s first surgical robot for open microsurgery. This robotic assistant is clinically and commercially available after the medical device CE-mark was issued by notified body DEKRA recently. Microsure’s MUSA is developed by a team of microsurgeons and engineers, creating a high-precision robotic assistant that is compatible with current operating techniques, workflow, instruments and other OR-equipment. It enhances surgical performance by stabilizing and scaling down the surgeon’s movements during complex microsurgical procedures on sub-millimeter scale.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190607005175/en/
Microsure’s MUSA e.g. enables lymphatic surgery on lymph vessels smaller than 0.3 mm in diameter. Plastic surgeons at Maastricht University Medical Center+ were the first to use MUSA to surgically treat lymphedema in a patient. This world's premier super-microsurgical intervention with 'robot hands' took place in 2017. Maastricht University Medical Center+ is now conducting several follow up clinical research projects with MUSA, in different fields of microsurgery. Other European hospitals are expected to start clinical studies this year.
Microsurgery procedures with MUSA
Surgical procedures that maximally benefit from Microsure’s MUSA are complex surgeries on small tissue structures –for instance LVA (Lymphovenous Anastomosis) surgery, pediatric vascalar surgery, free flap surgery, finger and hand replantation – when human precision is the limiting factor because of physiological tremor, poor accessibility or fatigue. Various studies and pilots have proven safe and effective clinical use of the device.
ISO 13485 certification
Microsure also received the ISO 13485 certificate, another major milestone. The ISO certification assures that Microsure is adhering to the highest standards in quality management and regulatory compliance procedures to develop, manufacture, and test its products and services. ISO 13485:2016 is the latest update to ISO requirements for a comprehensive quality management system for the design and manufacture of medical devices.
Microsure
Microsure is a medical device company in Eindhoven (The Netherlands) founded by Eindhoven University of Technology and Maastricht University Medical Center in 2016, funded by Innovation Industries Fund. Microsure’s focus is to improve patients’ quality of life through developing robot systems for microsurgery. Its current product is MUSA, the world’s first surgical robot for open microsurgery. MUSA has been designed by microsurgeons and engineers, specifically for microsurgical applications. MUSA provides superhuman precision for microsurgeons, enabling new interventions that are currently impossible to perform by hand. www.microsure.nl
View source version on businesswire.com: https://www.businesswire.com/news/home/20190607005175/en/
Contact:
Microsure Lars Schiemanck (CEO) l.schiemanck@microsure.nl +31 686 692 887
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lebrikizumab Delivered Significant Skin Clearance and Improved Disease Severity in Children With Moderate-to-severe Atopic Dermatitis16.3.2026 11:53:00 CET | Press release
Almirall announces positive, top-line results from Phase 3 ADorable-1 trialADorable-1 met co-primary efficacy endpoints, with 63% of paediatric patients achieving meaningful skin improvement (EASI-75) and 44% reaching clear or almost clear skin (IGA 0,1) at week 16.Key secondary endpoints showed significant itch relief (Pruritus NRS ≥4 point improvement), reduced overall disease severity (EASI-90) and improved quality of life (CDLQI ≥6-Point Improvement) in children and adolescents with moderate-to-severe atopic dermatitis treated with lebrikizumab.Skin conditions can have a profound physical and emotional impact on people’s lives1, and Atopic Dermatitis (AD) peaks in childhood – with around 60% of cases appearing within the first year of life2. Almirall, S.A. (ALM), a global biopharmaceutical company focused on medical dermatology, today announced positive, top-line results from the pivotal Phase 3 ADorable-1 trial evaluating efficacy and safety of lebrikizumab for children and adoles
Experian Marks a Breakthrough in Consumer AI with the Next Evolution of Its Virtual Assistant16.3.2026 11:00:00 CET | Press release
Smarter, more adaptive assistant advances personalized, conversational financial guidance powered by trusted data Experian today unveiled the next evolution of the Experian Virtual Assistant, EVA™, a significant advancement in its Consumer First AI strategy that expands personalized, conversational financial guidance to millions of consumers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260316538160/en/ Experian today unveiled the next evolution of the Experian Virtual Assistant, EVA™. “This next generation of EVA reflects the direction of our consumer AI strategy,” said Debbie Hsu, Executive Vice President of Product, Experian Consumer Services. “We are bringing together conversational AI, personalization, and our trusted data foundation to deliver guidance that is intuitive, relevant, and actionable. Our focus is on helping consumers make smarter financial decisions in ways that feel simple and empowering.” Built to scal
Triton Partners Successfully Closes Fund 6 at €5.5 Billion Target16.3.2026 08:00:00 CET | Press release
Triton Partners today announces the successful close of its sixth flagship mid-market fund (“T6” or “the Fund”) on target at €5.5 billion, the largest fund to date for Triton. The Fund has raised capital from new and existing investors globally, underscoring the continued confidence of Limited Partners in Triton’s European mid-market strategy and the Firm’s ability to build better businesses. Triton’s Mid-Market buyout (TMM) strategy focuses on its core sectors of industrial technology, business services and healthcare. As a responsible owner of choice, T6 will invest where its market and investment insights provide an edge, positioning the firm to capitalise on attractive opportunities, supported by the Accelerator Unit, Europe’s largest value creation team. T6 seeks to maintain the strong performance of previous funds, all having achieved top quartile returns. Reflecting this consistent track record, Triton was recently named as one of three European managers in the HEC global univer
Syngenta deepens research capabilities with QuantumBasel partnership16.3.2026 08:00:00 CET | Press release
At the World Agri-Tech Innovation Summit, Syngenta, a global leader in agricultural innovation, today announced it is exploring how quantum computing can help farmers meet the growing demands of food production in a changing climate. The company has partnered with QuantumBasel, Switzerland's first commercial quantum computing hub, to apply quantum technologies to agricultural research and development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260316646014/en/ Ion trap, which uses electromagnetic fields to confine and control ions for use as quantum bits (qubits). Farmers worldwide face mounting pressure to produce more food sustainably amid unpredictable weather and evolving pest and disease challenges. Meeting these demands requires new scientific approaches that go beyond what classical computing can deliver, particularly when it comes to understanding the complex molecular and biological systems that underpin crop sc
NTT DATA Launches GCC Innovation Acceleration Program to Support Innovation Creation by Global Companies16.3.2026 04:30:00 CET | Press release
NTT DATA, a global leader in AI, digital business and technology services, today announced the launch of its GCC Innovation Acceleration Program. This is designed to support global companies rapidly establishing and scaling their strategic offshore hubs in India, including Global Capability Centers (GCC) and other innovation and delivery hubs. Launched in October 2025, the program aims to support more than 50 companies over the next three years. The demand for highly skilled IT personnel has expanded globally, and as a result, companies are increasingly using overseas bases to meet innovation needs. NTT DATA identified India as a stand-out market to launch the GCC Innovation Acceleration Program because of its abundance of talent and strong technical capabilities. India’s Global Capability Center ecosystem, delivering IT services and back-office functions to multinationals, is poised for strong growth of nearly 70%, targeting $110 billion in 2030 from the current $65 billion, according
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom